Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Old Drugs, New Data
Researchers at IAS reported on the benefits of once-daily tenofovir + FTC + efavirenz as initial therapy, described a new needle-free injection system for T-20, and announced the impending availability of lopinavir/ritonavir in tablet formulation.
Sign In
Don't yet have a username or password?
Register now for
Journal Watch e-mail alerts and unlimited online
access to articles 6 months after publication.
Subscribe now for
Full, immediate online access to all Journal Watch content and services.
Already a subscriber? Activate your subscription to receive full online access.
Get full site access with a 7-day site pass for $19